Overview
Melatonin is an endogenous neurohormone produced by the pineal gland that plays a central role in regulating the sleep-wake cycle and circadian rhythms. Beyond its role as a natural sleep regulator, melatonin is now one of the most widely used supplements globally, with applications ranging from jet lag management to immune support and inflammation reduction.
Unlike prescription sleeping medications, melatonin is available over-the-counter in most countries as an oral supplement, making it accessible to millions seeking natural sleep support and other health benefits. However, its regulatory status varies—it's classified as a prescription medication in several countries including the UK, Germany, and Australia for doses above 2mg, reflecting ongoing debates about its long-term safety at pharmacological doses.
This guide synthesizes the current evidence on melatonin's benefits, mechanisms, proper dosing, and potential side effects to help you make informed decisions about whether supplementation is appropriate for your health goals.
Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting melatonin supplementation, particularly if you are pregnant, breastfeeding, have autoimmune conditions, or take medications.
How It Works: Mechanism of Action
Melatonin functions through multiple mechanisms in the body, making it a multitarget compound rather than a single-action supplement.
Circadian Rhythm Regulation
Melatonin's primary mechanism involves activation of MT1 and MT2 G-protein coupled receptors located in the suprachiasmatic nucleus of the hypothalamus—the brain's central circadian clock. MT1 receptor activation inhibits neuronal firing to reduce alertness and promote sleepiness, while MT2 activation helps phase-shift circadian rhythms, making it particularly effective for conditions like delayed sleep phase syndrome and jet lag.
This receptor-mediated action directly suppresses wakefulness signals, providing a physiological rather than pharmacological approach to sleep induction.
Antioxidant and Free Radical Scavenging
Beyond circadian effects, melatonin acts as a direct free radical scavenger, meaning it neutralizes harmful oxidative molecules independent of receptor binding. Additionally, it upregulates endogenous antioxidant enzymes including superoxide dismutase and glutathione peroxidase—the body's own defense systems against oxidative stress.
This antioxidant capacity underlies many of melatonin's broader health applications, from inflammation reduction to immune support.
Evidence by Health Goal
Melatonin has been studied across numerous health domains. Here's what the research shows, organized by evidence tier.
Sleep Quality (Tier 4 — Strong Evidence)
Sleep is melatonin's most well-researched and clinically validated application.
A meta-analysis of 23 randomized controlled trials (RCTs) found that melatonin reduced Pittsburgh Sleep Quality Index (PSQI) scores by 1.24 points compared to placebo (95% CI -1.77 to -0.71, p<0.001), representing a moderate clinical effect. For breast cancer patients specifically, a meta-analysis of 5 RCTs demonstrated a Hedges' g effect size of -0.79 (p<0.001) on sleep quality.
These results show that melatonin reliably improves sleep onset latency and overall sleep architecture across diverse populations. Effective doses typically range from 0.5-5mg orally, with effects emerging consistently across studies.
Heart Health (Tier 4 — Strong Evidence)
Melatonin demonstrates consistent cardiovascular benefits across multiple parameters.
Multiple meta-analyses of RCTs show systolic blood pressure reductions of 2.34-3.43 mmHg and diastolic reductions of 3.33 mmHg versus placebo. In patients with metabolic disorders, these reductions were substantially larger, with standardized mean differences of -0.87 for systolic and -0.85 for diastolic blood pressure across 8 RCTs.
These blood pressure improvements translate to meaningful reductions in cardiovascular disease risk, particularly when combined with other lifestyle interventions.
Anti-Inflammation (Tier 4 — Strong Evidence)
Melatonin shows robust evidence for reducing inflammatory markers associated with chronic disease.
A meta-analysis of 63 RCTs found that melatonin reduced:
- C-reactive protein by 0.59 mg/L
- Tumor necrosis factor-alpha (TNF-α) by 1.61 pg/mL
- Interleukin-6 (IL-6) by 6.43 pg/mL
A separate meta-analysis of 13 studies (n=749) demonstrated TNF-α decreases of 2.24 pg/ml (95% CI -3.45, -1.03; p<0.001) and IL-6 reductions of 30.25 pg/ml (95% CI -41.45, -19.06; p<0.001). These inflammatory reductions are observed primarily in disease populations including diabetes, metabolic syndrome, and multiple sclerosis.
Sleep in Atopic Dermatitis (Tier 3 — Probable Evidence)
A randomized controlled trial of 80 adults with atopic dermatitis found that 10 mg melatonin daily for 4 weeks significantly reduced SCORAD disease severity (p<0.001), pruritus severity (p=0.006), and improved sleep quality (p<0.05) and quality of life (p=0.003). A meta-analysis of 3 pediatric RCTs showed melatonin 3-6 mg/day reduced sleep onset latency (SMD -0.63, p=0.0009) and SCORAD scores by 6.60 points (p=0.0002).
Fat Loss (Tier 3 — Probable Evidence)
While melatonin is not a primary weight-loss agent, meta-analyses suggest modest effects.
A meta-analysis of 23 RCTs found body weight reductions with a standardized mean difference of 0.48 (p<0.01), though heterogeneity was high (I²=92%), indicating variable effects across studies. Hip circumference showed more consistent reductions of 1.21 cm (95% CI: 1.94 to -0.49, p=0.001) in a meta-analysis of 28 RCTs (n=1,543).
The clinical meaningfulness of these changes remains unclear, making melatonin best suited as an adjunct rather than a primary intervention for weight management.
Liver Health (Tier 3 — Probable Evidence)
A meta-analysis of 63 RCTs found melatonin reduced alanine aminotransferase (ALT) by 2.61 IU/L (95% CI: -4.87, -0.34) and increased total antioxidant capacity by 0.15 mmol/L (95% CI: 0.08, 0.22) in cardiometabolic populations. In patients with non-alcoholic fatty liver disease (NAFLD), melatonin significantly reduced gamma-glutamyltransferase by 33.37 IU/L and alkaline phosphatase by 8.40 IU/L, though effects on ALT were inconsistent.
Injury Recovery & Athletic Performance (Tier 3 — Probable Evidence)
Melatonin demonstrates benefits for post-exercise recovery and injury rehabilitation.
A meta-analysis of 19 RCTs (n=266) found moderate effects on endurance performance (SMD = 0.58, 95% CI: 0.29–0.87, p < 0.001). Notably, melatonin significantly reduced creatine kinase levels (SMD = 0.59, 95% CI: 0.29–0.89, p < 0.0001), indicating reduced muscle damage markers. In a study of high-intensity exercise in trained males (n=12), 6 mg melatonin improved 5-meter shuttle run total distance, fatigue index, sprint decrement percentage, and enhanced perceived recovery status up to 72 hours post-exercise.
For COPD rehabilitation specifically, patients receiving 3 mg melatonin daily showed 71 meters greater improvement in 6-minute walk test versus placebo over 12 weeks (p<0.01, n=39). Melatonin also improved COPD health status by 11 points versus 3 points placebo (p<0.01) and quality of life by 6.9 points versus 1.9 points placebo (p<0.01).
Energy & Fatigue (Tier 3 — Probable Evidence)
A meta-analysis of 9 RCTs examining cancer-related fatigue found melatonin improved fatigue versus placebo (SMD: -0.23, 95% CI: -0.44 to -0.01, p=0.04), with significant effects only at treatment durations of 13 weeks or longer (SMD: -0.38, p=0.02).
Hormone Balance & Sexual Function (Tier 3 — Probable Evidence)
For sexual health, melatonin increased International Index of Erectile Function scores by 5.59 points versus placebo in methadone patients (n=54, RCT, P=0.005). However, a meta-analysis of 7 RCTs (n=497 menopausal women) found no significant improvements in sexual function despite improvements in other menopausal symptoms.
For hormonal outcomes more broadly, fasting blood glucose was reduced by 11.63 mg/dL (95% CI: -19.16, -4.10) in a cardiometabolic meta-analysis of 63 RCTs.
Gut Health (Tier 3 — Probable Evidence)
For functional dyspepsia, a meta-analysis of 3 RCTs (n=148) found melatonin improved symptoms with an odds ratio of 4.96 (95% CI 2.19-11.27, p<0.001) using fixed-effects analysis, though random-effects modeling was non-significant, suggesting potential publication bias.
Joint & Bone Health (Tier 2 — Emerging Evidence)
A meta-analysis of 13 articles found positive results in fibromyalgia, osteoarthritis, and osteoporosis/osteopenia, with melatonin well tolerated and producing mild side effects. However, most evidence comes from animal studies—human RCT data remains limited.
Cognition (Tier 3 — Probable Evidence)
Results are mixed. In type 2 diabetes patients (n=154, observational), 5 mg melatonin daily for 12 weeks improved Montreal Cognitive Assessment scores versus placebo. However, in a larger mild cognitive impairment RCT (n=40), 25 mg melatonin nightly for 12 weeks showed no significant differences in cognition versus placebo despite >80% adherence.
Immune Support (Tier 3 — Probable Evidence)
Melatonin demonstrates immunomodulatory effects, particularly in autoimmune conditions. In systemic lupus erythematosus patients, 10 mg melatonin daily for 12 weeks reduced serum MDA (oxidative stress marker) by 33% versus baseline (p=0.003) and significantly versus placebo (p=0.004), though disease activity did not change (n=25, RCT).
In multiple sclerosis patients (n=102), 5 mg melatonin daily for 90 days increased SOD antioxidant activity and decreased MDA, improving some quality-of-life subscales.
Muscle Growth (Tier 1 — No Evidence)
Melatonin has not demonstrated efficacy for muscle growth in humans. While it increases total antioxidant capacity and glutathione levels in chronic disease populations, no human RCTs have measured muscle mass, strength, or lean mass as primary outcomes. In a 12-month RCT of 41 thalassemia patients, melatonin 20 mg/day did not significantly improve lumbar spine bone mineral density versus placebo (p = 0.069).
Longevity (Tier 2 — Emerging Evidence)
While animal studies suggest anti-aging potential, human evidence is lacking. One small RCT (n=40) in mild cognitive impairment showed no significant differences from placebo in brain oxidative stress, cognition, mood, or sleep—though the trial was underpowered for efficacy. Age-related decline in endogenous melatonin is well documented, with maximum melatonin levels dropping from 49.3 pg/mL in younger cohorts to 27.8 pg/mL in aged populations.